Deregulated cytokine network and defective Th1 immune response in multiple myeloma

Clinical and Experimental Immunology

Volumn 125, Issue 2, 2001, Pages 190-197

  Frassanito, M A ^a   Cusmai, A ^a   Dammacco, F ^a,b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b DIMO Section of Internal Medicine and Clinical Oncology   (Italy)

Author keywords

IL 10; IL 12; IL 6; Multiple myeloma; Th1 Th2 lymphocytes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6;

ADULT; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MONONUCLEAR CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANTIGENS, CD3; CELLS, CULTURED; CYTOKINES; CYTOPLASM; DENDRITIC CELLS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; T-LYMPHOCYTES; TH1 CELLS;

EID: 0034881738     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01582.x     Document Type: Article

References (44)

1. Identifying strategies for immune intervention
2. Human tumor antigens for cancer vaccine development
3. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
4. + cytotoxic T lymphocyte
5. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
6. Functional diversity of helper T lymphocytes
7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
8. Type 1 vs type 2 cytokine released by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
9. IL-12 induces T helper-1 directed antitumor response
10. + T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer
11. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
12. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
13. Inteleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
14. Myeloma proteins as tumor-specific transplantation antigens
15. Multiple myeloma: Increasing evidence for a multistep transformation process
16. Anti-idiotypic antibodies in patients with monoclonal gammopathies. Relation to tumor load
17. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
18. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells
19. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status
20. A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma
21. + cells of myeloma patients
22. + cells and apoptosis suppress T-cell functions in multiple myeloma
23. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients
24. Multiple myeloma, macroglobulinemia and monoclonal gammopathies
25. A clinical staging system for multiple myeloma
26. Th1 polarization of the immune response in Behçet's disease: A putative pathogenetic role of IL-12
27. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma
28. Th1 and Th2 in human diseases
29. Interleukin 10 (IL-10) inhibits human lymphocyte interferon-γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells
30. Function and clinical use of interleukin-12
31. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
32. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma
33. Serum interleukin-10 in plasma-cell dyscrasias
34. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy?
35. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors
36. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma
37. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells
38. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma
39. + T cells
40. Augmentation of naives Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF
41. Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4
42. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1
43. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells
44. Autocrine IL-6 production and highly malignant multiple myeloma: Relationship with resistance to drug-induced apoptosis